Related Experiment Videos
p53 mutagenesis in Klatskin tumors
S Jonas1, G Springmeier, R Tauber
1Department of Surgery, Virchow Klinikum, Humboldt University, Berlin, Germany.
Abstract:
Mutagenesis of the p53 tumor-suppressor gene represents the most common genetic alteration in human malignancies but has not yet been investigated in Klatskin tumors. Cancerous and normal liver tissues were obtained from 12 patients after surgical resection of Klatsin tumors. Genomic DNA was extracted and served as a template for PCR amplification and sequencing of a 1,574-bp fragment of the p53 gene comprising the exons 5 through 8. Immunohistochemical expression analysis was performed using five different antibodies. Missense mutations were detected in 2 of 12 patients--one transversion on codon 273 (Arg --> Leu) and a transition on codon 168 (His --> Arg). In all specimens, immunohistochemistry was negative regarding a nuclear overexpression. An apparent clinicopathologic impact of p53 mutations was not observed. This report on mutagenesis of the p53 gene in Klatskin tumors shows that the most commonly mutated tumor suppressor gene in human cancers is also mutated in a subset of patients with Klatskin tumors. Assessment of a clinical or pathological impact of p53 mutagenesis on Klatskin tumors requires evaluation in larger studies.
Insights
The p53 tumor suppressor gene was mutated in a subset of Klatskin tumors, the most common genetic alteration in human cancers. Further studies are needed to assess the clinical impact of these p53 mutations.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The p53 tumor suppressor gene is frequently mutated in human cancers.
- Klatskin tumors are a rare type of cholangiocarcinoma with limited genetic investigation.
- p53 gene mutations are the most common genetic alterations in human malignancies.
Purpose of the Study:
- To investigate the frequency and nature of p53 gene mutations in Klatskin tumors.
- To analyze the expression of p53 protein in Klatskin tumors.
- To explore the potential clinicopathological significance of p53 mutations in this cancer type.
Main Methods:
- Genomic DNA extraction from 12 Klatskin tumor and adjacent normal liver tissues.
- Polymerase chain reaction (PCR) amplification and sequencing of p53 exons 5-8.
- Immunohistochemical analysis using five distinct antibodies for p53 expression.
Main Results:
- Missense mutations in the p53 gene were identified in 2 out of 12 (16.7%) Klatskin tumor patients.
- Detected mutations included a transversion at codon 273 (Arg to Leu) and a transition at codon 168 (His to Arg).
- No nuclear overexpression of p53 protein was observed via immunohistochemistry in any specimen.
Conclusions:
- The p53 tumor suppressor gene is indeed mutated in a subset of Klatskin tumors.
- The observed p53 mutations did not show an apparent clinicopathological impact in this cohort.
- Larger studies are required to determine the clinical and pathological significance of p53 mutagenesis in Klatskin tumors.